O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus

Bibliographic Details
Main Authors:	Laura Geraldino-Pardilla, Subhashis Banerjee, Ann E Clarke, Eric Morand, Cristina Arriens, Ronald van Vollenhoven, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Lupus Science and Medicine

Similar Items

P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
by: Joseph F Merola, et al.
Published: (2024-03-01)

P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
by: Richard Furie, et al.
Published: (2024-03-01)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
by: Ian M. Catlett, et al.
Published: (2023-01-01)

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
by: S Banerjee, et al.
Published: (2022-10-01)

LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
by: Bindu Murthy, et al.
Published: (2023-07-01)

LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
by: Chun Wu, et al.
Published: (2023-07-01)

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr.
Published: (2023-03-01)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
by: Shan Jing, et al.
Published: (2023-11-01)

Paisleys and other textile designs from India /
by: Prakash, K
Published: (1994)

Deucravacitinib in the treatment of psoriasis
by: Tomás Estevinho, et al.
Published: (2023-12-01)

PaisleyTrees: A Size-Invariant Tree Visualization
by: Katayoon Etemad, et al.
Published: (2014-10-01)

The Language of Conflict in Northern Ireland: Gerry Adams vs. Ian Paisley
by: Kim Grego
Published: (2010-03-01)

25 Disease modification in SLE: an introduction
by: Ronald van Vollenhoven
Published: (2023-09-01)

A Practical Study of Control in Objected-Oriented–Functional–Logic Programming with Paisley
by: Baltasar Trancón y Widemann, et al.
Published: (2017-01-01)

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
by: Arianna Zhang, BS, et al.
Published: (2024-03-01)

Treatment of oral lichen planus using deucravacitinib
by: Mindy Vu, BS, et al.
Published: (2024-02-01)

22 New and approved therapies for SLE: Anifrolumab
by: Ronald van Vollenhoven
Published: (2022-04-01)

Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients
by: Elizabeth Park, et al.
Published: (2021-10-01)

LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
by: Richard Furie, et al.
Published: (2024-03-01)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
by: Ana Martins, et al.
Published: (2023-05-01)

01 Understanding and treating SLE: a new era is dawning
by: Ronald van Vollenhoven
Published: (2020-09-01)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023-05-01)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
by: Nicole Bouché, BS, et al.
Published: (2023-09-01)

06 Interferon inhibition and the future management of SLE
by: Eric Morand
Published: (2021-04-01)

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
by: Jingyue Qiu, et al.
Published: (2023-09-01)

Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults
by: Reinaldo S. Dos Santos, et al.
Published: (2023-10-01)

Associations of metabolic syndrome in SLE
by: Eric Morand, et al.
Published: (2020-12-01)

Targeting DORIS Remission and LLDAS in SLE: A Review
by: Agner R. Parra Sánchez, et al.
Published: (2023-10-01)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023-05-01)

05 Approved biologics for SLE: which to try first and in which patients? – The case for belimumab
by: Ronald van Vollenhoven
Published: (2023-09-01)

The mechanism of allosteric inhibition of protein tyrosine phosphatase 1B.
by: Shuai Li, et al.
Published: (2014-01-01)

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
by: Sarah Oliel, et al.
Published: (2023-11-01)

Allosteric communication across the native and mutated KIT receptor tyrosine kinase.
by: Elodie Laine, et al.
Published: (2012-01-01)

06 Approved biologics for SLE: which to try first and in which patients? – The case for anifrolumab
by: Eric Morand
Published: (2023-09-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.
by: Alexandros P Grammatikos, et al.
Published: (2013-01-01)

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2024-12-01)

The protein architecture and allosteric landscape of HNF4α
by: Fraydoon Rastinejad
Published: (2023-09-01)

617 Evaluation of SLE outcome measures in telemedicine: interim analysis results
by: Cynthia Aranow, et al.
Published: (2022-12-01)

PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash
by: X Huang, et al.
Published: (2022-10-01)